Amyn Habib, M.D. Professor School Medical School Department Neurology Graduate Programs Cancer Biology Biography Dr. Amyn Habib is a Professor in the Department of Neurology at UT Southwestern Medical Center, and a Staff Physician at the VA North Texas Health Care System/ Dallas VA Medical Center. As a physician scientist, Dr. Habib attends to patients with neurological disorders and also runs an active basic science research laboratory. He received his medical degree from Dow Medical College in Karachi, Pakistan. He did his internship at Henry Ford Hospital in Detroit, followed by a Neurology Residency at the University of Chicago Medical Center. He then undertook research fellowships at the University of Chicago and at Beth Israel Deaconess Medical Center/Harvard Medical School. He was an Instructor of Neurology at Harvard Medical School prior to joining UT Southwestern. His research interests include investigation of growth factor signaling pathways in glioblastoma and other cancers. His work has elucidated the interaction between normal and mutant epidermal growth factor receptors (EGFR) in glioblastoma. In addition, his laboratory has identified and characterized interactions between inflammatory and oncogenic signaling pathways in cancer. His laboratory has provided a fundamental insight in the biology of EGFR signaling by demonstrating that constitutive and ligand-induced EGFR signaling triggers distinct and mutually exclusive downstream signaling networks. More recent work in his laboratory has focused on mechanisms of resistance to targeted treatment in cancer with a particular focus on glioblastoma and lung cancer and identified therapeutic approaches to overcome the resistance of glioblastoma and non-small cell lung cancer (NSCLC) to EGFR inhibition. Additional areas of active interest in the laboratory include mechanisms that regulate the invasion and proliferation of tumor cells in glioblastoma. His research is funded by the NIH and by the Department of Veteran’s Affairs. Education Medical School Dow Medical College - Pakistan (1986), Medicine Research Interest Mechanisms of resistance to targeted treatment in cancer Molecular Mechanisms regulating glioblastoma invasion and proliferation The role of inflammation in gliomagenesis Publications Featured Publications EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation. Guo G, Gong K, Beckley N, Zhang Y, Yang X, Chkheidze R, Hatanpaa KJ, Garzon-Muvdi T, Koduru P, Nayab A, Jenks J, Sathe AA, Liu Y, Xing C, Wu SY, Chiang CM, Mukherjee B, Burma S, Wohlfeld B, Patel T, Mickey B, Abdullah K, Youssef M, Pan E, Gerber DE, Tian S, Sarkaria JN, McBrayer SK, Zhao D, Habib AA, Nat Cell Biol 2022 Aug Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. Gong K, Guo G, Beckley NA, Yang X, Zhang Y, Gerber DE, Minna JD, Burma S, Zhao D, Akbay EA, Habib AA, Nat Commun 2021 Dec 12 1 7014 EGFR inhibition triggers an adaptive response driven by cooptation of antiviral signaling pathways in lung cancer Gong K, Guo G, Panchani N, Bender M, Gerber DE, Minna JD, Fattah F, Gao B, Peyton M, Kernstine K, Mukherjee B, Burma S, Chiang CM, Zhang S, Sathe AA, Xing C, Dao KH, Zhao D, Akbay EA, and Habib AA*. Nat. Cancer 2020 1, 394 TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA J Clin Invest. 2018 Jun 1;128(6):2500-2518 A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Guo G, Gong K, Ali S, Ali N, Shallwani S, Hatanpaa KJ, Pan E, Mickey B, Burma S, Wang DH, Kesari S, Sarkaria JN, Zhao D, Habib AA Nat. Neurosci. 2017 Aug;20(8):1074-1084. doi: 10.1038/nn.4584. Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks Chakraborty S, Li L, Puliyappadamba VT, Guo G, Hatanpaa KJ, Mickey B, Souza R, Vo P, Herz J, Chen MR, Boothman DA, Pandita TK, Wang DH, Sen GC, Habib AA. Nature Communications 2014 Dec 15, 2014. DOI:10.1038/ncomms86811 1-15 Crucial roles of the BRCA1-BARD1 E3 ubiquitin ligase activity in homology-directed DNA repair. Wang M, Li W, Tomimatsu N, Yu CH, Ji JH, Alejo S, Witus SR, Alimbetov D, Fitzgerald O, Wu B, Wang Q, Huang Y, Gan Y, Dong F, Kwon Y, Sareddy GR, Curiel TJ, Habib AA, Hromas R, Dos Santos Passos C, Yao T, Ivanov DN, Brzovic PS, Burma S, Klevit RE, Zhao W, Mol Cell 2023 Oct 83 20 3679-3691.e8 Transfer Learning Approach to Vascular Permeability Changes in Brain Metastasis Post-Whole-Brain Radiotherapy. Arledge CA, Crowe WN, Wang L, Bourland JD, Topaloglu U, Habib AA, Zhao D, Cancers (Basel) 2023 May 15 10 Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer. Liu Y, Crowe WN, Wang L, Petty WJ, Habib AA, Zhao D, Nano Res 2023 Apr 16 4 5300-5310 Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Liu Y, Wang L, Song Q, Ali M, Crowe WN, Kucera GL, Hawkins GA, Soker S, Thomas KW, Miller LD, Lu Y, Bellinger CR, Zhang W, Habib AA, Petty WJ, Zhao D, Nat Nanotechnol 2021 Dec Results 1-10 of 59 1 2 3 4 5 Next Last Honors & Awards Clinical Investigator AwardNational Cancer Institute (1999)
